Abstract: Compositions of, methods of making, and methods of using alkaline earth phosphate bone cements are disclosed. A bone cement composition includes a powder comprising a basic source of calcium, magnesium, or strontium, a setting solution comprising H3PO4 and a buffer, and a biocompatible polymer that is incorporated into the setting solution. The powder is mixed with the setting solution to form a bone cement paste that either (a) sets into a hardened mass, or (b) is irradiated with electromagnetic radiation to form dry powders, the dry powders then being mixed with a second setting solution to form a radiation-assisted bone cement paste that sets into a hardened mass.
Type:
Grant
Filed:
January 31, 2013
Date of Patent:
September 4, 2018
Assignee:
The University of Toledo
Inventors:
Sarit B. Bhaduri, Huan Zhou, Anand K. Agarwal, Vijay K. Goel
Abstract: The present disclosure provides a preparation method of rumen protected glucose, comprising the following steps: (1) preparing glucose into a pellet and drying; (2) fluidizing the pellet in a fluidized bed after drying; and (3) coating melted aliphatic alcohol and/or saturated fatty acid onto the surface of the pellet located in the fluidized bed to obtain a rumen protected bypass glucose particle. The prepared rumen-protected glucose could go through the rumen of ruminant effectively; and the availability of coating layer in ruminant increases, making the coated glucose be released completely and fully utilized by ruminant, so ketosis or subclinical ketosis and fatty liver disease of the ruminants in perinatal stage could be prevented and reduced effectively, the postpartum weight loss could be reduced, and the cycle conception rate and the milk yield could be increased.
Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, which alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.
Abstract: The invention generally relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer that is anchored to the backing layer by siliconization.
Abstract: Disclosed are compositions that include treated biodiesel glycerin. The disclosed compositions may be utilized as soil-amendments for controlling pests, weeds and for enhancing growth of plants. The biodiesel glycerin utilized in the disclosed compositions may be treated by one or more steps including neutralization, heating, refluxing, condensing, and distilling.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
July 31, 2018
Assignee:
Auburn University
Inventors:
Rodrigo Rodriguez-Kabana, Robert H. Walker
Abstract: The invention relates to: —a biomimetic collagen-hydroxyapatite composite material comprising an at least partially fibrous collagen scaffold including mature native collagen fibers possessing triple helicity as shown by Circular Dichroism Spectroscopy, wherein those mature native collagen fibers are at least partially covered with epitactically grown crystals of nanocrystalline hydroxyapatite, whereby the epitactically grown nanocrystals have the same morphology as human bone mineral and the same size as human bone mineral, i.e.
Abstract: A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
July 10, 2018
Assignee:
Corium International, Inc.
Inventors:
Parminder Singh, Eun Soo Lee, Amit K. Jain
Abstract: The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption.
Abstract: The present invention relates to a microneedle and a microneedle array. More specifically, it relates to a microneedle and a microneedle array capable of injecting a drug into the surface layer or horny layer of the skin easily, safely and efficiently.
Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
July 24, 2017
Date of Patent:
May 15, 2018
Assignee:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. For example, in some embodiments, tissue patches are made by applying a compressive force to a liquid medium comprising fibrinogen (and/or fibrin) between two surfaces (e.g., within a syringe or other chamber). A filter can be placed within or near the volume in which the compressive force is applied to the liquid medium such that unwanted material (e.g., water, blood cells, and the like) is passed through the filter while desirable components (e.g., fibrin, fibrinogen, and/or other desirable components) are retained by the filter to form the patch. In this way, the concentration of fibrin (and/or fibrinogen) within the liquid medium can be increased, potentially dramatically, as the compressive force is applied to the liquid-containing composition.
Abstract: The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g.
Type:
Grant
Filed:
August 12, 2016
Date of Patent:
April 3, 2018
Assignee:
NEW JERSEY INSTITUTE OF TECHNOLOGY
Inventors:
Ecevit Bilgili, Rajesh Dave, Anagha Bhakay, Mohammad Azad
Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.
Abstract: Provided is a transdermal delivery system consisting of a backing layer, a drug-containing matrix layer, and a release layer, wherein the drug-containing matrix layer includes (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a mixture of high molecular weight polyisobutylene having a weight-average molecular weight ranging from 400,000 to 3,000,000 and low molecular weight polyisobutylene having a weight-average molecular weight ranging from 25,000 to 300,000 as an adhesive, and (c) a permeation enhancer in not more than 3% by weight based on the total weight of the drug-containing matrix layer.
Abstract: The present invention provides a band seal for hard capsules filled with PEG, particularly a low-molecular-weight PEG, PEG 200 to 600, the band seal being capable of effectively preventing content leakage through the gap between the body and cap of the capsule; and a liquid for preparing the band seal. The present invention further provides a hard capsule filled with PEG, particularly a low-molecular-weight PEG, PEG 200 to 600, the filled capsule being prevented content leakage through the gap between the body and cap of the capsule. The band seal can be prepared using a polyvinyl alcohol, a polyvinyl alcohol copolymer, or a mixture thereof as a main component.
Abstract: The present invention relates to alternan-carboxylic acid esters, to processes for the preparation of alternan-carboxylic acid esters, and to compositions comprising alternan-carboxylic acid esters and to the use of alternan-carboxylic acid esters. The invention relates to alternan-carboxylic acid esters which are emulsifiers.
Abstract: Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
February 27, 2018
Assignee:
BioDelivery Sciences International, Inc.
Abstract: The present invention concerns a new composition based on pellets of lipoic acid in a lipophilic medium, if necessary combined with other active ingredients.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
November 21, 2017
Assignee:
Olon S.p.A.
Inventors:
Paolo Magri', Antonio Nardi, Annibale Salvi, Flavio Villani